Preclinical evaluation of fap-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

HIGHLIGHTS

• who: Dirk Zboralski from the B Pharmaceuticals GmbH, Magnusstrau00dfe, Berlin, Germany have published the article: Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy, in the Journal: (JOURNAL)

SUMMARY

To address the low tumor retention of the FAPI series, the authors developed the FAP-2286 compound, based on a novel class of FAP-targeting modalities, that utilizes cyclic peptides as binding motifs. The in_vitro and in_vivo characterization of FAP-2286 and its metal complexes are reported and compared to FAPI-46. Cell‑based binding assay FAP-expressing WI . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.